药效动力学模型优化舒巴坦的剂量方案。
Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
机构信息
Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand.
出版信息
Antimicrob Agents Chemother. 2013 Jul;57(7):3441-4. doi: 10.1128/AAC.00342-13. Epub 2013 May 6.
Abstract
The aim of this study was to reveal population pharmacokinetics and assess the efficacies of various dosage regimens of sulbactam in terms of the probability of target attainment with this agent over a range of MICs. Monte Carlo simulations were performed to determine the probability of attaining specific pharmacodynamic targets. The results indicated that a regimen consisting of a 4-h infusion of 3 g of sulbactam every 8 h would be an alternative treatment option for less-susceptible pathogens.
摘要
本研究旨在揭示人群药代动力学，并评估不同剂量方案的舒巴坦在一系列 MIC 值范围内针对该药物达到特定药效学目标的概率。通过蒙特卡罗模拟来确定达到特定药效学目标的概率。结果表明，每 8 小时输注 3 g 舒巴坦 4 小时的方案可能是针对低敏感性病原体的替代治疗选择。
相似文献
1
Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
Antimicrob Agents Chemother. 2013 Jul;57(7):3441-4. doi: 10.1128/AAC.00342-13. Epub 2013 May 6.
2
Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
J Infect Chemother. 2015 Apr;21(4):284-9. doi: 10.1016/j.jiac.2014.12.005. Epub 2014 Dec 26.
3
Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7236-7244. doi: 10.1128/AAC.01669-16. Print 2016 Dec.
4
Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
Eur J Pharm Sci. 2019 Aug 1;136:104940. doi: 10.1016/j.ejps.2019.05.018. Epub 2019 May 25.
5
Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations.
J Antimicrob Chemother. 2024 Sep 3;79(9):2227-2236. doi: 10.1093/jac/dkae218.
6
Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Using Checkerboard Information.
Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.
7
In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.
8
Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection.
Microb Pathog. 2020 Jan;138:103809. doi: 10.1016/j.micpath.2019.103809. Epub 2019 Oct 18.
9
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
Int J Antimicrob Agents. 2014 Jun;43(6):547-52. doi: 10.1016/j.ijantimicag.2014.02.012. Epub 2014 Mar 30.
10
High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01268-16. Print 2017 Mar.
引用本文的文献
1
Sulbactam for carbapenem-resistant infections: a literature review.
JAC Antimicrob Resist. 2025 Apr 12;7(2):dlaf055. doi: 10.1093/jacamr/dlaf055. eCollection 2025 Apr.
2
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
3
Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Infections-A Meta-Analysis.
Antibiotics (Basel). 2024 Sep 23;13(9):907. doi: 10.3390/antibiotics13090907.
4
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.
J Antimicrob Chemother. 2023 Apr 3;78(4):1034-1040. doi: 10.1093/jac/dkad042.
5
Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an Pharmacodynamic Model.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01680-20.
6
Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):735-747. doi: 10.1007/s13318-020-00643-3.
7
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02183-19.
8
Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.
Crit Care. 2017 Dec 20;21(1):319. doi: 10.1186/s13054-017-1916-6.
9
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.
Infect Dis Ther. 2017 Jun;6(2):149-172. doi: 10.1007/s40121-017-0149-y. Epub 2017 Mar 4.
10
Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7236-7244. doi: 10.1128/AAC.01669-16. Print 2016 Dec.
本文引用的文献
1
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Int J Antimicrob Agents. 2012 Nov;40(5):434-9. doi: 10.1016/j.ijantimicag.2012.07.014. Epub 2012 Sep 7.
2
3
Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
J Infect. 2008 Jun;56(6):432-6. doi: 10.1016/j.jinf.2008.04.002. Epub 2008 May 23.
4
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.
Scand J Infect Dis. 2007;39(1):38-43. doi: 10.1080/00365540600951184.
5
Prevention of resistance: a goal for dose selection for antimicrobial agents.
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50. doi: 10.1086/344653.
6
Completely resistant Acinetobacter baumannii strains.
Infect Control Hosp Epidemiol. 2002 Aug;23(8):477-9. doi: 10.1086/502091.
7
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.
Emerg Infect Dis. 2002 Aug;8(8):827-32. doi: 10.3201/eid0805.020014.
8
Optimization in development of acetaminophen syrup formulation.
Drug Dev Ind Pharm. 2002 Mar;28(3):345-51. doi: 10.1081/ddc-120002850.
9
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.
J Antimicrob Chemother. 2001 Apr;47(4):479-82. doi: 10.1093/jac/47.4.479.
10
beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
Clin Infect Dis. 1997 Mar;24(3):494-7. doi: 10.1093/clinids/24.3.494.
Zotero 插件